Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

被引：4
|
作者：
Kim, Young-Hak [1 ]
机构：
[1] Kyoto Univ, Kyoto, Japan
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2019年 / 380卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：989 / 990
页数：2
相关论文
共 50 条
  • [41] Durvalumab after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC) - a German radiation oncology survey
    Kaesmann, Lukas
    Eze, Chukwuka
    Taugner, Julian
    Roengvoraphoj, Olarn
    Belka, Claus
    Manapov, Farkhad
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [42] Durvalumab as a maintenance therapy after a definitive chemoradiotherapy for a stage III non-small cell lung cancer - an interim analysis of the PACIFIC trial
    Kawecki, Maciej
    ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 (03): : 167 - 170
  • [43] Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: a retrospective analysis
    Katsui, Kuniaki
    Ogata, Takeshi
    Sugiyama, Soichi
    Yoshio, Kotaro
    Kuroda, Masahiro
    Hiraki, Takao
    Kiura, Katsuyuki
    Maeda, Yoshinobu
    Toyooka, Shinichi
    Kanazawa, Susumu
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [44] Sarcopenia is associated with poor prognosis after chemoradiotherapy in patients with stage III non-small-cell lung cancer: a retrospective analysis
    Kuniaki Katsui
    Takeshi Ogata
    Soichi Sugiyama
    Kotaro Yoshio
    Masahiro Kuroda
    Takao Hiraki
    Katsuyuki Kiura
    Yoshinobu Maeda
    Shinichi Toyooka
    Susumu Kanazawa
    Scientific Reports, 11
  • [45] Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer
    Heymach, John V.
    Harpole, David
    Mitsudomi, Tetsuya
    Taube, Janis M.
    Galffy, Gabriella
    Hochmair, Maximilian
    Winder, Thomas
    Zukov, Ruslan
    Garbaos, Gabriel
    Gao, Shugeng
    Kuroda, Hiroaki
    Ostoros, Gyula
    Tran, Tho V.
    You, Jian
    Lee, Kang-Yun
    Antonuzzo, Lorenzo
    Papai-Szekely, Zsolt
    Akamatsu, Hiroaki
    Biswas, Bivas
    Spira, Alexander
    Crawford, Jeffrey
    Le, Ha T.
    Aperghis, Mike
    Doherty, Gary J.
    Mann, Helen
    Fouad, Tamer M.
    Reck, Martin
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (18): : 1672 - 1684
  • [46] Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial
    Senan, S.
    Ozguroglu, M.
    Daniel, D.
    Villegas, A.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Faivre-Finn, C.
    Paz-Ares, L.
    Wu, Y. L.
    Mann, H.
    Dennis, P. A.
    Antonia, S. J.
    ESMO OPEN, 2022, 7 (02)
  • [47] Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer
    Horita, Nobuyuki
    Fujiwara, Yu
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (03): : 287 - 288
  • [48] Is durvalumab the solution for unresectable stage III non-small cell lung cancer?
    Duma, Narjust
    Mansfield, Aaron S.
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S89 - S93
  • [49] Durvalumab for Patients with Stage III EGFR-Mutated Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy
    Aredo, J. V.
    Hellyer, J. A.
    Neal, J. W.
    Padda, S. K.
    McCoach, C. E.
    Riess, J. W.
    Cabebe, E. C.
    Loo, B. W.
    Diehn, M.
    Wakelee, H. A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S15 - S15
  • [50] Interim Analysis of Neoadjuvant Chemoradiotherapy and Durvalumab for Potentially Resectable Stage III Non-Small Cell Lung Cancer (NSCLC)
    Hong, M. H.
    Ahn, B.
    Kim, H. R.
    Lim, S. M.
    Lee, S.
    Park, S. Y.
    Lee, C. Y.
    Lee, J. G.
    Kim, D. J.
    Lee, S. H.
    Yoon, H. I.
    Lee, C. G.
    Cho, J.
    Shim, H. S.
    Kim, T.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S194 - S195
12345